AR113224A1 - Conjugados de anticuerpo que comprenden un agonista de sting - Google Patents
Conjugados de anticuerpo que comprenden un agonista de stingInfo
- Publication number
- AR113224A1 AR113224A1 ARP180101063A ARP180101063A AR113224A1 AR 113224 A1 AR113224 A1 AR 113224A1 AR P180101063 A ARP180101063 A AR P180101063A AR P180101063 A ARP180101063 A AR P180101063A AR 113224 A1 AR113224 A1 AR 113224A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody conjugates
- sting agonist
- conjugates including
- immunoconjugates
- methods
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title abstract 4
- 229940044665 STING agonist Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762491879P | 2017-04-28 | 2017-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR113224A1 true AR113224A1 (es) | 2020-02-19 |
Family
ID=62165655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101063A AR113224A1 (es) | 2017-04-28 | 2018-04-25 | Conjugados de anticuerpo que comprenden un agonista de sting |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3615080A1 (ja) |
JP (1) | JP2020517700A (ja) |
CN (1) | CN110799218A (ja) |
AR (1) | AR113224A1 (ja) |
WO (1) | WO2018200812A1 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3380126A4 (en) | 2015-11-25 | 2019-07-24 | LegoChem Biosciences, Inc. | ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS |
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
AU2018364708A1 (en) | 2017-11-10 | 2020-05-21 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
EP3505188A1 (en) * | 2017-12-29 | 2019-07-03 | Invivogen | Pro-cyclic dinucleotide conjugates for cytokine induction |
CA3099680A1 (en) | 2018-05-09 | 2019-11-14 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
AU2019277679A1 (en) * | 2018-06-01 | 2020-12-24 | Eisai R&D Management Co., Ltd. | Methods for the treatment of bladder cancer |
EP3820477A4 (en) * | 2018-07-10 | 2022-07-13 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES |
WO2020089815A1 (en) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
EP3873938A1 (en) * | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody conjugates comprising sting agonists |
JOP20210159A1 (ar) * | 2018-12-21 | 2023-01-30 | Novartis Ag | أجسام مضادة لـ pmel17 ومترافقات منها |
MA55805A (fr) * | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
JP2022531899A (ja) | 2019-05-09 | 2022-07-12 | アリゴス セラピューティクス インコーポレイテッド | Stingモジュレータとしての修飾環状ジヌクレオシド化合物 |
MX2021013657A (es) * | 2019-05-10 | 2022-02-21 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco. |
TW202100184A (zh) | 2019-05-20 | 2021-01-01 | 瑞士商諾華公司 | Mcl-1抑制劑抗體-藥物結合物及使用方法 |
BR112022000854A2 (pt) | 2019-07-19 | 2022-03-08 | Immunesensor Therapeutics Inc | Conjugados anticorpo - agonista de sting e seu uso em imunoterapia |
BR112022001931A2 (pt) | 2019-08-02 | 2022-06-21 | Mersana Therapeutics Inc | Derivados de bis-[n-((5-carbamoil)-1h-benzo[d]imidazol-2-il)-pirazol-5-carboxamida e compostos relacionados como agonistas de sting (estimulador de genes de interferon) para o tratamento de câncer |
MX2022002152A (es) * | 2019-08-21 | 2022-05-18 | Scripps Research Inst | Agonistas biciclicos del estimulador de genes de interferon sting. |
KR20210028544A (ko) * | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
WO2021046426A1 (en) * | 2019-09-06 | 2021-03-11 | Sperovie Biosciences, Inc. | Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies |
US20230074385A1 (en) * | 2019-12-23 | 2023-03-09 | Eisai R&D Management Co., Ltd. | Method for producing eribulin-based antibody-drug conjugate |
CA3168368A1 (en) * | 2020-03-06 | 2021-09-10 | Masayuki Ishizaki | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
EP4218826A3 (en) * | 2020-04-02 | 2023-10-25 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists |
TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
US20230149560A1 (en) | 2020-04-20 | 2023-05-18 | Massachusetts Institute Of Technology | Lipid compositions for delivery of sting agonist compounds and uses thereof |
CN115803032A (zh) | 2020-05-15 | 2023-03-14 | 免疫传感器治疗股份有限公司 | Sting激动剂与免疫检查点抑制剂的联合治疗 |
CN111592570B (zh) * | 2020-05-15 | 2022-04-29 | 清华大学 | 新型sting激动剂及其制备方法和应用 |
AU2021374958A1 (en) | 2020-11-09 | 2023-06-22 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
CA3215049A1 (en) | 2021-04-10 | 2022-10-13 | Baiteng ZHAO | Folr1 binding agents, conjugates thereof and methods of using the same |
WO2022223619A1 (en) | 2021-04-20 | 2022-10-27 | Institut Curie | Compositions and methods for use in immunotherapy |
EP4326768A1 (en) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
JP2024526874A (ja) | 2021-07-23 | 2024-07-19 | イミューンセンサー セラピューティクス、インコーポレイテッド | サイトカインとのstingアゴニスト併用療法 |
CN118524854A (zh) * | 2021-12-17 | 2024-08-20 | 北京加科思新药研发有限公司 | 包含可用作sting激动剂的新型化合物的化合物-连接基构建体及其用途 |
US20240218011A1 (en) | 2022-07-21 | 2024-07-04 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
WO2024100449A1 (en) * | 2022-11-08 | 2024-05-16 | Legochem Biosciences, Inc. | Sting agonists |
WO2024153127A1 (zh) * | 2023-01-18 | 2024-07-25 | 泰励生物科技(上海)有限公司 | 抗体偶联药物及其用途 |
WO2024189481A1 (en) | 2023-03-10 | 2024-09-19 | Novartis Ag | Panras inhibitor antibody-drug conjugates and methods of use thereof |
GB202304385D0 (en) | 2023-03-24 | 2023-05-10 | Prostate Cancer Res | Combinatorial IL-15 therapy |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
LT2281006T (lt) | 2008-04-30 | 2017-11-27 | Immunogen, Inc. | Skersinių jungčių linkeriai ir jų panaudojimas |
IN2015DN02913A (ja) | 2012-11-30 | 2015-09-18 | Novartis Ag | |
EA201590396A1 (ru) | 2012-12-13 | 2015-12-30 | Адуро Биотек, Инк. | Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения |
MX2015010146A (es) | 2013-02-08 | 2016-05-31 | Novartis Ag | Sitios especificos para modificar anticuerpos para hacer inmunoconjugados. |
EP2991655B1 (en) | 2013-04-29 | 2024-04-10 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
EP3653637A1 (en) * | 2013-05-18 | 2020-05-20 | Aduro BioTech, Inc. | Compositions and methods for activating "stimulator of interferon genes"-dependent signalling |
EP3071229A4 (en) | 2013-11-22 | 2017-05-10 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
JP6462006B2 (ja) | 2014-06-04 | 2019-01-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Stingのモジュレーターとしての環式ジヌクレオチド |
CN107148424B (zh) | 2014-12-16 | 2021-01-08 | 凯拉治疗股份公司 | 用于诱导细胞因子的环状二核苷酸 |
WO2016145102A1 (en) * | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
US20180117171A1 (en) * | 2015-04-01 | 2018-05-03 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
WO2017004499A1 (en) | 2015-07-02 | 2017-01-05 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of viral infection |
WO2017011622A1 (en) | 2015-07-14 | 2017-01-19 | Spring Bank Pharmaceuticals, Inc. | Compounds and compositions that induce rig-i-and other pattern recongnition receptors |
JP6878405B2 (ja) * | 2015-07-29 | 2021-05-26 | ノバルティス アーゲー | Pd−1に対する抗体分子を含む組み合わせ治療 |
MX2018001814A (es) | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
EP3386536A4 (en) * | 2015-12-07 | 2019-07-31 | Opi Vi- IP Holdco LLC | COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF |
CN106540256A (zh) * | 2016-03-27 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 |
WO2018009652A1 (en) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
AU2017293781B2 (en) | 2016-07-06 | 2022-12-22 | Invox Pharma Limited | Compounds, compositions, and methods for the treatment of disease |
JP2019521138A (ja) | 2016-07-15 | 2019-07-25 | スペロビー・バイオサイエンシズ・インコーポレイテッド | 疾患の治療のための化合物、組成物、および方法 |
WO2018013887A1 (en) | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
-
2018
- 2018-04-25 AR ARP180101063A patent/AR113224A1/es unknown
- 2018-04-26 JP JP2019558397A patent/JP2020517700A/ja active Pending
- 2018-04-26 EP EP18724677.2A patent/EP3615080A1/en not_active Withdrawn
- 2018-04-26 CN CN201880043438.4A patent/CN110799218A/zh active Pending
- 2018-04-26 WO PCT/US2018/029570 patent/WO2018200812A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2020517700A (ja) | 2020-06-18 |
EP3615080A1 (en) | 2020-03-04 |
WO2018200812A1 (en) | 2018-11-01 |
CN110799218A (zh) | 2020-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR113224A1 (es) | Conjugados de anticuerpo que comprenden un agonista de sting | |
ECSP18038868A (es) | Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll | |
CL2018003758A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458) | |
CL2018003406A1 (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo. | |
CL2019003050A1 (es) | Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinación. | |
CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
CO2017010618A2 (es) | Anticuerpos contra icos | |
ECSP19072235A (es) | Anticuerpos anti-ILT4 y fragmentos de unión a antígeno | |
CO2017004516A2 (es) | Anticuerpos anti-ox40 humanizados | |
CY1124230T1 (el) | Αγωνιστης υποδοχεα γλυκοκορτικοειδων και ανοσοσυζευγματα αυτου | |
CL2016002667A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
CR20170131A (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
UY38433A (es) | Conjugados de anticuerpo dc–sign que comprenden agonistas de sting | |
BR112017026027A2 (pt) | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 | |
CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
CO2018005393A2 (es) | Anticuerpos anti-htra1 y métodos de uso de los mismos | |
CL2018002050A1 (es) | Conjugados anticuerpo-fármaco dirigidos a gcc. | |
AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
CO2017010692A2 (es) | Construcciones de calicheamicina y sus métodos de uso | |
CO2020008886A2 (es) | Métodos para el procesamiento de materias primas de hidrocarburos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |